Online There is a significant number of patients still not at their LDL-cholesterol goal. The talk focuses on the benefit of providing access to different available non-statin lipid-lowering agents for appropriate ASCVD patients together with a discussion of their impact on vascular inflammation, endothelial function, and clinical outcome.
Dimitris Tousoulis, Athens, GR
Charalambos Antoniades, Oxford, UK
PCSK9 functions beyond plasmatic LDL-cholesterol regulation
Lina Badimon, Barcelona, Spain
During the Q&A, participants will have the opportunity to interact with the chairs and speaker by asking their questions verbally using the “Raise hand” feature or in written form using the "Q&A" module. Chairs and speakers can answer directly in the module (publicly or privately) or discuss live during the Q&A.
European Society of Cardiology
European Heart House
Les Templiers
2035 Route des Colles
CS 80179 Biot
06903, Sophia Antipolis, FR
Tel.
+33.4.92.94.76.00
Our mission: To reduce the burden of cardiovascular disease.